港股异动 | 康方生物(09926)午前涨超10% 依沃西疗法一线治疗结直肠癌III期临床首例患者入组

智通财经2025-07-17

智通财经APP获悉，康方生物(09926)午前涨超10%，截至发稿，涨10.24%，报138.9港元，成交额15.06亿港元。消息面上，7月16日，据康方生物官微消息，康方生物自主研发的全球首创PD-1/VEGF双特异性抗体新药依达方®(通用名：依沃西单抗注射液)用于一线治疗晚期转移性结直肠癌(pMMR/MSS型 mCRC)的注册性III期临床研究(AK112-312/HARMONi-GI6)已...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2552117748?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-17 11:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2552117748","market":"hk","top_or_hot":-1,"title":"港股异动 | 康方生物(09926)午前涨超10% 依沃西疗法一线治疗结直肠癌III期临床首例患者入组","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，康方生物(09926)午前涨超10%，截至发稿，涨10.24%，报138.9港元，成交额15.06亿港元。消息面上，7月16日，据康方生物官微消息，康方生物自主研发的全球首创PD-1/VEGF双特异性抗体新药依达方®(通用名：依沃西单抗注射液)用于一线治疗晚期转移性结直肠癌(pMMR/MSS型 mCRC)的注册性III期临床研究(AK112-312/HARMONi-GI6)已...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1318850.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 康方生物(09926)午前涨超10% 依沃西疗法一线治疗结直肠癌III期临床首例患者入组</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 康方生物(09926)午前涨超10% 依沃西疗法一线治疗结直肠癌III期临床首例患者入组\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-17 11:36 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1318850.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，康方生物(09926)午前涨超10%，截至发稿，涨10.24%，报138.9港元，成交额15.06亿港元。消息面上，7月16日，据康方生物官微消息，康方生物自主研发的全球首创PD-1/VEGF双特异性抗体新药依达方®(通用名：依沃西单抗注射液)用于一线治疗晚期转移性结直肠癌(pMMR/MSS型 mCRC)的注册性III期临床研究(AK112-312/HARMONi-GI6)已...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1318850.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0348784397.USD","symbol_name":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1318850.html","article_id":"2552117748","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2552117748","pubTimestamp":1752723365,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，康方生物午前涨超10%，截至发稿，涨10.24%，报138.9港元，成交额15.06亿港元。消息面上，7月16日，据康方生物官微消息，康方生物自主研发的全球首创PD-1/VEGF双特异性抗体新药依达方用于一线治疗晚期转移性结直肠癌的注册性III期临床研究已完成首例患者入组。注册性III期研究AK112-312/HARMONi-GI6的启动，将进一步验证依沃西联合化疗在该患者群体中的优越性，有望成为MSS/pMMR型mCRC患者全新且高效的一线免疫治疗选择。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","BK4134":"信息科技咨询与其它服务","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","BK1574":"生物医药B类股","LU0348783233.USD":"安联东方收入型 CI A Dis美元","09926":"康方生物","BK1161":"生物科技","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU1720050803.USD":"安联全方位中国股票基金","III":"信息服务","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD"},"translate_title":"Changes in Hong Kong stocks | Akeso Biotech (09926) rose more than 10% before noon, the first patient of phase III clinical trial of Evocil therapy for the first-line treatment of colorectal cancer was enrolled","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1,"III":1},"content_text":"智通财经APP获悉，康方生物(09926)午前涨超10%，截至发稿，涨10.24%，报138.9港元，成交额15.06亿港元。消息面上，7月16日，据康方生物官微消息，康方生物自主研发的全球首创PD-1/VEGF双特异性抗体新药依达方®(通用名：依沃西单抗注射液)用于一线治疗晚期转移性结直肠癌(pMMR/MSS型 mCRC)的注册性III期临床研究(AK112-312/HARMONi-GI6)已完成首例患者入组。这项针对mCRC一线治疗的随机、对照、多中心III期临床试验，是公司推动依沃西疗法攻克全球巨大临床未决需求的行动之一，彰显了公司对依沃西突破性临床价值潜力的强大信心，也是依沃西持续构建全球领先优势的重要举措。依沃西方案的初步研究数据优于现有标准治疗的数据，以及既往披露的PD-1免疫检查点抑制剂的相关数据，这提示依沃西联合方案具有的潜在突破性临床价值，有望填补这类患者的免疫治疗空白。注册性III期研究AK112-312/HARMONi-GI6的启动，将进一步验证依沃西联合化疗在该患者群体中的优越性，有望成为MSS/pMMR型mCRC患者全新且高效的一线免疫治疗选择。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2552117748","isCrawlerRequest":true}